{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"28.3","value":"0"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"77.6","value":"0"},{"groupId":"OG002","lowerLimit":"4.7","upperLimit":"37.7","value":"16.7"},{"groupId":"OG003","lowerLimit":"22.4","upperLimit":"100.0","value":"100"},{"groupId":"OG004","lowerLimit":"0.0","upperLimit":"39.3","value":"0"},{"groupId":"OG005","lowerLimit":"0.0","upperLimit":"23.8","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"18"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"11"}],"units":"Participants"}],"description":"Percentage of participants who achieved an objective response of Complete Response (CR) or Partial Response (PR) per Response Evaluation Criteria in Solid Tumor (RECIST) v1.1. CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had to have reduction in short axis to \\<10 mm. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Disease progression is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study including baseline; or the appearance of one or more new lesions.","dispersionType":"90% Confidence Interval","groups":[{"description":"Dose expansion in TNBC participants. Rebastinib 50 mg BID PO in 21-day cycles in combination with carboplatin administered by IV infusion at AUC5 at Day 1 of each 21-day cycle.","id":"OG000","title":"Part 2 Cohort 1 Expansion Rebastinib 50 mg + Carboplatin AUC5"},{"description":"Dose expansion in TNBC participants. Rebastinib 100 mg BID PO in 21-day cycles in combination with carboplatin administered by IV infusion at AUC5 at Day 1 of each 21-day cycle.","id":"OG001","title":"Part 2 Cohort 1 Expansion Rebastinib 100 mg + Carboplatin AUC5"},{"description":"Dose expansion in platinum-sensitive ovarian cancer participants. Rebastinib 50 mg BID PO in 21-day cycles in combination with carboplatin administered by IV infusion at AUC5 at Day 1 of each 21-day cycle.","id":"OG002","title":"Part 2 Cohort 2 Expansion Rebastinib 50 mg + Carboplatin AUC5"},{"description":"Dose expansion in platinum-sensitive ovarian cancer participants. Rebastinib 100 mg BID PO in 21-day cycles in combination with carboplatin administered by IV infusion at AUC5 at Day 1 of each 21-day cycle.","id":"OG003","title":"Part 2 Cohort 2 Expansion Rebastinib 100 mg + Carboplatin AUC5"},{"description":"Dose expansion in mesothelioma participants. Rebastinib 50 mg BID PO in 21-day cycles in combination with carboplatin administered by IV infusion at AUC5 at Day 1 of each 21-day cycle.","id":"OG004","title":"Part 2 Cohort 3 Expansion Rebastinib 50 mg + Carboplatin AUC5"},{"description":"Dose expansion in mesothelioma participants. Rebastinib 100 mg BID PO in 21-day cycles in combination with carboplatin administered by IV infusion at AUC5 at Day 1 of each 21-day cycle.","id":"OG005","title":"Part 2 Cohort 3 Expansion Rebastinib 100 mg + Carboplatin AUC5"}],"paramType":"NUMBER","populationDescription":"Expansion Phase mITT participants that were evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Time from CR or PR to disease progression or death due to any cause (Up to 1.53 years)","title":"Objective Response Rate (ORR) (Dose Expansion Phase)","type":"PRIMARY","unitOfMeasure":"percentage of participants"}